Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,401 to 1,420 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: serious adverse events | 948 of 3,256 927 of 3,248 | 0.6 points -1.6 to 2.8 | 6,504 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| IV Rt-PA Cohort vs Non-reperfusion Cohort: deaths from any cause | 360 of 3,247 396 of 3,247 | -1.1 points -2.7 to 0.5 | 6,494 | NCT05395338 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients |
| Ivabradine vs Placebo: serious adverse events | 1,369 of 3,232 1,481 of 3,260 | -3.1 points -5.5 to -0.7 | 6,492 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Pharmacist Arm vs Usual Care: deaths from any cause | 330 of 3,239 334 of 3,239 | -0.1 points -1.6 to 1.4 | 6,478 | NCT04071951 Pharmacist Intervention to Reduce Post-Hospitalization Utilization |
| Pharmacist Arm vs Usual Care: serious adverse events | 1,485 of 3,239 1,438 of 3,239 | 1.5 points -1.0 to 3.9 | 6,478 | NCT04071951 Pharmacist Intervention to Reduce Post-Hospitalization Utilization |
| Empagliflozin 10 mg vs Placebo: serious adverse events | 765 of 3,234 798 of 3,229 | -1.1 points -3.1 to 1.0 | 6,463 | NCT04509674 EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) |
| Apix 2.5mg BID vs Enox 40mg QD: serious adverse events | 611 of 3,184 601 of 3,217 | 0.5 points -1.4 to 2.4 | 6,401 | NCT00457002 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness |
| Etanercept vs nbDMARDs: serious adverse events | 944 of 3,529 744 of 2,864 | 0.8 points -1.4 to 2.9 | 6,393 | NCT01646385 Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry |
| Social Proof vs Reframing Side Effects and Adverse Reactions: Number of Employees Who Opened Emails After 3 Days | 1,481 of 3,198 1,398 of 3,190 | 2.5 points 0.0 to 4.9 | 6,388 | NCT04728594 Emails Promoting COVID-19 Vaccination Among Healthcare Workers |
| Social Proof vs Reframing Side Effects and Adverse Reactions: Number of Employees Who Clicked Scheduling Links After 3 Days | 562 of 3,198 382 of 3,190 | 5.6 points 3.9 to 7.3 | 6,388 | NCT04728594 Emails Promoting COVID-19 Vaccination Among Healthcare Workers |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: deaths from any cause | 151 of 2,923 175 of 3,372 | -0.0 points -1.1 to 1.1 | 6,295 | NCT03890588 Chronic Kidney Disease Clinical Decision Support |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: serious adverse events | 541 of 2,923 543 of 3,372 | 2.4 points 0.5 to 4.3 | 6,295 | NCT03890588 Chronic Kidney Disease Clinical Decision Support |
| Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of All-cause Mortality | 497 of 3,131 526 of 3,132 | -0.9 points -2.8 to 0.9 | 6,263 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | 512 of 3,131 610 of 3,132 | -3.1 points -5.0 to -1.2 | 6,263 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| Dapa 10 mg vs Placebo: deaths from any cause | 510 of 3,131 533 of 3,132 | -0.7 points -2.6 to 1.1 | 6,263 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of Cardiovascular Death | 231 of 3,131 261 of 3,132 | -1.0 points -2.3 to 0.4 | 6,263 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| Dapa 10 mg vs Placebo: serious adverse events | 1,454 of 3,126 1,508 of 3,127 | -1.7 points -4.2 to 0.8 | 6,253 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| Simvastatin Plus Ezetimibe vs Placebo: End-stage Renal Disease Among All Patients Not on Dialysis at the Time of Randomization to Simvastatin Plus Ezetimibe Versus Placebo | 1,057 of 3,117 1,084 of 3,130 | -0.7 points -3.1 to 1.6 | 6,247 | NCT00125593 Study of Heart and Renal Protection |
| FSC DPI vs FP DPI: Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period | 265 of 3,107 309 of 3,101 | -1.4 points -2.9 to 0.0 | 6,208 | NCT01462344 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old |
| FSC DPI vs FP DPI: Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 27 of 3,107 21 of 3,101 | 0.2 points -0.3 to 0.6 | 6,208 | NCT01462344 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=71
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02504216-sae",
"title": "Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: serious adverse events",
"summary": "948 of 3256 against 927 of 3248; risk difference 0.6 points, 95% interval -1.6 to 2.8; NCT02504216, Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities",
"record": "/library/comparisons/NCT02504216-sae",
"nct_id": "NCT02504216",
"kind": "serious-adverse-events",
"participants": 6504,
"risk_difference": {
"value": 0.005748387213904471,
"lower": -0.01626477001928316,
"upper": 0.027752744407118172
},
"group_1": "948 of 3,256",
"group_2": "927 of 3,248",
"difference": "0.6 points",
"interval": "-1.6 to 2.8",
"trial_title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities"
},
{
"id": "NCT05395338-deaths",
"title": "IV Rt-PA Cohort vs Non-reperfusion Cohort: deaths from any cause",
"summary": "360 of 3247 against 396 of 3247; risk difference -1.1 points, 95% interval -2.7 to 0.5; NCT05395338, 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients",
"record": "/library/comparisons/NCT05395338-deaths",
"nct_id": "NCT05395338",
"kind": "deaths",
"participants": 6494,
"risk_difference": {
"value": -0.011087157376039422,
"lower": -0.026706846379030563,
"upper": 0.004524621804563027
},
"group_1": "360 of 3,247",
"group_2": "396 of 3,247",
"difference": "-1.1 points",
"interval": "-2.7 to 0.5",
"trial_title": "1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=72",
"request_id": "nxcBjbS3eH-GqKT4"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant